Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) presented preclinical data for ZL-1503, a bispecific antibody targeting IL-13 and IL-31Rα pathways ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE